Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

NCT06254469 | Recruiting Phase 3 FDA Drug

• 1 other identifier: CMK-0301
• Study Type: interventional
• Target: 230
• Locations: 1 country
• Sites: 1

Brief Summary

CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT. The secondary objectives include: (1) To demonstrate the feasibility of F-18 FNT-PET in differentiation of participants with suspected chronic traumatic encephalopathy (CTE) from those with suspected Alzheimer's disease (AD) by trained image readers, (2) To evaluate disease progression in participants with suspected CTE or AD and (3) To evaluate the correlation between F-18 FNT-PET regional and summary visual reads scan and other assessments.

Conditions

Alzheimer Disease; Chronic Traumatic Encephalopathy

Outcome Measures

Primary Outcomes (6)

• Accuracy of F-18 FNT-PET in prediction of clinical decline

  The correlation between predictive development of neurodegeneration as made from F-18 FNT-PET and score change from baseline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at the 2-year Follow-up Visit

  2 years

• Assessment of the safety of F-18 FNT using adverse events and serious adverse events.

  Adverse events and serious adverse events will be monitored in patients following F-18 FNT administration.

  2 years

• Assessment of the safety of F-18 FNT using vital signs.

  A patients body temperature, respiratory rate, sitting radial pulse rate, and sitting systolic and diastolic blood pressures will be monitored in patients following F-18 FNT administration.

  2 years

• Assessment of the safety of F-18 FNT using clinical laboratory assessments.

  A patients complete blood count with differential, free T4 Index, Vitamin B12 serum, chemistry panel (glucose, calcium, sodium, potassium, carbon dioxide, chlorine, albumin and total protein, ALP, ALT, AST, bilirubin, BUN, creatinine), benzodiazepines, uric acid, thyroid-stimulating hormone, and cholesterol will be monitored in patients following F-18 FNT administration.

  2 years

• Assessment of the safety of F-18 FNT using electrocardiograms

  12-Lead electrocardiograms (ECGs) will be performed for all participants at Screening and in-person Follow-up Visit(s). Triplicate 12-lead ECG measurements will be obtained approximately 2 minutes apart. A repeat 12-lead ECG recording may be obtained to confirm ECG findings at the discretion of the Investigator. A full assessment of the ECG will be performed including P Wave, QRS Complex, and QT Interval.

  2 years

• Assessment of the safety of F-18 FNT using the Suicide Behavior Questionnaire-Revised

  The Suicide Behavior Questionnaire-Revised will be given and assessed in patients following F-18 FNT administration.

  2 years

Secondary Outcomes (28)

• Feasibility of F-18 FNT-PET to differentiate suspected CTE from suspected AD.

  2 years

• Evaluation of disease progression in participants with suspected CTE or AD using the CDR-SB at the 2-year follow-up visit.

  2 years

• Evaluation of disease progression in participants with suspected CTE or AD using the 36-Item Short Form Survey (SF-36).

  2 years

• Evaluation of disease progression in participants with suspected CTE or AD using the STOP-BANG Questionnaire for Sleep Apnea.

  2 years

• Evaluation of disease progression in participants with suspected CTE or AD using the Pittsburgh Sleep Quality Index.

  2 years

Other Outcomes (1)

• Correlation of F-18 FNT binding patterns neuropathology at autopsy.

  2 years

Study Arms (3)

Part A - Lead in

OTHER

Part A plans to enroll 50 participants (approximately 20 participants with mild cognitive impairment \[MCI\] due to suspected CTE, 20 participants with MCI due to suspected AD, and 10 age-matched healthy volunteers, whose age is within 3 years of any participants with MCI due to suspected CTE or AD in Part A).

Drug: [F-18]Flornaptitril

Part B - AD

EXPERIMENTAL

Part B plans to enroll 90 participants with MCI due to suspected AD for primary accuracy assessments of F-18 FNT-PET imaging.

Drug: [F-18]Flornaptitril

Part B - CTE

EXPERIMENTAL

Part B plans to enroll 90 participants with MCI due to suspected CTE from concussive and percussive injuries in approximately 1:1 ratio for primary accuracy assessments of F-18 FNT-PET imaging.

Drug: [F-18]Flornaptitril

Interventions

[F-18]Flornaptitril DRUG

All participants will receive a single dose of F-18 FNT during an imaging visit.

Part A - Lead in; Part B - AD; Part B - CTE

Eligibility Criteria

• Age: 45 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants with MCI enrolling in the trial must meet all the following criteria:
• a. All of the following features are required: i) Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure, progressive course; and at least 1 supportive feature ii) History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma iii) Head trauma exposure is repetitive in nature iv) Demonstrated progressive course v) Delayed symptom onset vi) Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (neuropsychological tests, visuospatial, memory, and language) b. Only 1 of the following supportive features is required: i) Emotional dysregulation: including depression, anxiety, agitation, aggression, paranoid ideation, deterioration of interpersonal relationships, or suicidality ii) Behavioral change: including violence, poor impulse control, socially inappropriate behavior, avolition, apathy, change in personality, or comorbid substance abuse iii) Motor disturbance: including bradykinesia, tremor, rigidity, gait instability, dysarthria, dysphagia, or ataxia 9. Participants with MCI due to suspected AD must meet all the following criteria:
• Diagnosis of MCI due to suspected AD according to workgroups of the Diagnostic Guidelines of the National Institute on Aging and Alzheimer's Association (NIA-AA)
• Documented evidence of memory decline with gradual onset and slow progression for at least 1 year. If medically documented evidence is not available, an informant may provide confirmatory evidence
• An MMSE-2 score of 22 to 30, inclusive, at the Screening Visit
• Biomarker positive based on predefined plasma p-tau cutoff
• Modified Hachinski Ischemic Score of ˂4 at the Screening Visit
• Cognitive deficits do not occur exclusively in the context of delirium
• Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia), or other medical condition (e.g., hypothyroidism)
• Medically healthy, at the age within 3 years of any participants with MCI due to suspected CTE or AD in Part A, and with no clinically relevant findings on physical examination or laboratory results
• Participants must have a trial partner who has frequent interaction with them (approximately \>3-4 times per week), will be present for all clinic visits, and can assist in compliance with trial procedures
• No cognitive impairment based upon cognitive assessment and as evaluated by the Investigator
• No first-degree family history of early-onset AD or other neurodegenerative diseases (prior to age 65)
• An MMSE-2 score ≥27.

You may not qualify if:

• Pregnant or breastfeeding
• Unable to remain still for duration of imaging procedure or have an inability to tolerate neuropsychological, clinical, or PET scan studies (e.g., head tremor that may cause head motion artifact, uncontrollable psychosis, acute suicidality)
• History of stroke, transient ischemic attack, seizures, or other condition of the head or neck within 12 months prior to the Screening Visit that, in the Investigator's opinion, might affect circulation to the head or image interpretation
• Preexisting major neurologic or other physical illness that could confound results (e.g., multiple sclerosis, diabetes, cancer)
• Psychiatric disorder such as mania, schizophrenia, anxiety, or depression (Geriatric Depression Scale ≥10), which in the Investigator's opinion, might interfere with completing trial procedures
• Condition or personal circumstance that, in the Investigator's opinion, might interfere with the collection of complete, good quality data
• History of significant prescription drug, non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin, or derivatives
• Previously received F-18 FNT at any time, or any other investigational product (IP) within the past 30 days
• History of allergic reactions to albumin, or severe anemia or cardiac failure in which case the use of albumin would be medically contraindicated
• Unstable cardiac disease or uncontrolled hypertension (systolic blood pressure \[BP\] \>170 mmHg or diastolic BP \>100 mmHg)
• Any use of benzodiazepines within 24 hours prior to all trial visits
• Plan to take ibuprofen or naproxen within 5 days before the PET scan
• Received any radioactive drugs or scans within the previous month or 10 half-lives of the drug, whichever is longer, or participated in imaging or other clinical research studies that might confound trial results
• Implants (e.g., implanted cardiac pacemakers or defibrillators, insulin pumps, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips, or other medical implants that have not been certified for MRI), a history of claustrophobia in MRI, or any contraindication for MRI
• History of any CT/MRI finding such as mass lesions or brain infection that are unrelated to the trial

Sponsors & Collaborators

• CereMark Pharma, LLC: lead

Study Sites (1)

Endeavor Health Systems

Evanston, Illinois, 60201, United States

RECRUITING

MeSH Terms

Conditions

Alzheimer Disease; Chronic Traumatic Encephalopathy

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Brain Injuries, Traumatic; Brain Injuries; Brain Injury, Chronic; Craniocerebral Trauma; Trauma, Nervous System; Brain Damage, Chronic; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Wounds and Injuries

Study Officials

• Chad Yucus, MD

  Endeavor Health System

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Henry M Chilton, PharmD

CONTACT

8654069859; hmchilton@ceremarkpharma.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 16, 2023
• First Posted: February 12, 2024
• Study Start: July 1, 2025
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): June 30, 2029
• Last Updated: July 30, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)